Synthetic candidate drugs, including the thiazolidinedione class of drugs and its derivatives, ertiprotafib, ISIS 113715, ISIS-PTP1BRx, trodusquemine, benzofuran, benzothiophene biphenyls, vanadium complexes, aminobenzoic acid, phosphonic acid, carboxylic acids, sulfonic acids, phosphonodifluoromethyl, phenylalanine derivatives, imides, etc., have been studied for ameliorating insulin resistance by inhibiting PTP1B [22,23,24,25]. The gene discussed is PTPN1; the disease is Insulin resistance.